Q1 Earnings Forecast for TG Therapeutics Issued By B. Riley

TG Therapeutics, Inc. (NASDAQ:TGTX) – Stock analysts at B. Riley issued their Q1 2025 earnings per share (EPS) estimates for TG Therapeutics in a research note issued on Tuesday, March 4th. B. Riley analyst M. Mamtani anticipates that the biopharmaceutical company will post earnings per share of $0.21 for the quarter. The consensus estimate for TG Therapeutics’ current full-year earnings is $0.08 per share. B. Riley also issued estimates for TG Therapeutics’ FY2026 earnings at $1.73 EPS.

A number of other equities analysts have also issued reports on TGTX. HC Wainwright reissued a “buy” rating and set a $55.00 price target on shares of TG Therapeutics in a report on Tuesday. JPMorgan Chase & Co. boosted their target price on TG Therapeutics from $30.00 to $43.00 and gave the stock an “overweight” rating in a research report on Monday, November 25th. Finally, StockNews.com upgraded TG Therapeutics from a “sell” rating to a “hold” rating in a research report on Tuesday. Two analysts have rated the stock with a hold rating and five have assigned a buy rating to the stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $40.67.

TG Therapeutics Stock Performance

NASDAQ TGTX opened at $35.19 on Thursday. The company has a quick ratio of 3.91, a current ratio of 4.59 and a debt-to-equity ratio of 1.27. TG Therapeutics has a 52-week low of $12.93 and a 52-week high of $37.58. The business’s 50-day moving average price is $30.92 and its 200 day moving average price is $28.38. The firm has a market cap of $5.48 billion, a P/E ratio of -351.86 and a beta of 2.30.

TG Therapeutics (NASDAQ:TGTX) last released its quarterly earnings results on Monday, March 3rd. The biopharmaceutical company reported $0.15 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.08 by $0.07. TG Therapeutics had a negative return on equity of 8.32% and a negative net margin of 5.42%. The firm had revenue of $108.19 million for the quarter, compared to analyst estimates of $100.67 million.

Institutional Investors Weigh In On TG Therapeutics

A number of institutional investors and hedge funds have recently bought and sold shares of the stock. Vanguard Group Inc. lifted its stake in TG Therapeutics by 1.4% in the 4th quarter. Vanguard Group Inc. now owns 15,596,480 shares of the biopharmaceutical company’s stock valued at $469,454,000 after buying an additional 209,190 shares in the last quarter. State Street Corp lifted its stake in shares of TG Therapeutics by 35.8% during the 3rd quarter. State Street Corp now owns 9,094,158 shares of the biopharmaceutical company’s stock worth $212,712,000 after purchasing an additional 2,398,015 shares during the period. Soleus Capital Management L.P. lifted its stake in shares of TG Therapeutics by 5.8% during the 4th quarter. Soleus Capital Management L.P. now owns 2,681,242 shares of the biopharmaceutical company’s stock worth $80,705,000 after purchasing an additional 146,702 shares during the period. Clearbridge Investments LLC purchased a new position in shares of TG Therapeutics during the 4th quarter worth $55,237,000. Finally, Northern Trust Corp lifted its stake in shares of TG Therapeutics by 8.6% during the 4th quarter. Northern Trust Corp now owns 1,532,929 shares of the biopharmaceutical company’s stock worth $46,141,000 after purchasing an additional 120,785 shares during the period. Hedge funds and other institutional investors own 58.58% of the company’s stock.

Insider Transactions at TG Therapeutics

In related news, CFO Sean A. Power sold 10,021 shares of the company’s stock in a transaction that occurred on Monday, January 6th. The stock was sold at an average price of $28.53, for a total value of $285,899.13. Following the sale, the chief financial officer now owns 660,611 shares of the company’s stock, valued at approximately $18,847,231.83. This represents a 1.49 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Corporate insiders own 10.50% of the company’s stock.

About TG Therapeutics

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.